CHA VACCINE RESEARCH INSTITUTE |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,645 KRW | -0.75% |
|
-1.59% | -17.79% |
| Sales 2022 | 179M 130K | Sales 2023 | 294M 212K | Capitalization | 151B 109M |
|---|---|---|---|---|---|
| Net income 2022 | -6.72B -4.85M | Net income 2023 | -1.75B -1.26M | EV / Sales 2022 | 544 x |
| Net cash position 2022 | 34.13B 24.64M | Net cash position 2023 | 34.57B 24.96M | EV / Sales 2023 | 396 x |
| P/E ratio 2022 |
-19.6
x | P/E ratio 2023 |
-86
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 59.32% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.75% | ||
| 1 week | -1.59% | ||
| 1 month | -6.35% | ||
| 3 months | -7.47% | ||
| 6 months | -9.63% | ||
| Current year | -17.79% |
1 week
4 630.00
4 830.00
1 month
4 620.005 050.00
Current year
4 400.006 100.00
1 year
4 100.007 660.00
3 years
4 100.0014 900.00
5 years
4 100.0014 900.00
10 years
4 100.0014 900.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jeong-Seon Yeom
CEO | Chief Executive Officer | 62 | 00-09-30 |
Jung-Ki Cho
PSD | President | 54 | 18-12-31 |
Seung-Rae Kim
AUD | Comptroller/Controller/Auditor | 66 | 20-08-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Min-Sik Park
BRD | Director/Board Member | 54 | 20-02-29 |
Jung-Jae Koh
BRD | Director/Board Member | 70 | 17-02-28 |
Dae-Gyu Oh
BRD | Director/Board Member | 71 | 21-02-28 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 4,645 | -0.75% | 46,725 |
| 24-05-30 | 4,680 | +0.11% | 50,087 |
| 24-05-29 | 4,675 | -1.99% | 71,312 |
| 24-05-28 | 4,770 | +0.63% | 60,802 |
| 24-05-27 | 4,740 | +0.42% | 75,638 |
End-of-day quote Korea S.E., May 30, 2024
More quotes
CHA Vaccine Research Institute Co Ltd is a Korea-based company principally engaged in the vaccines and immunotherapy research business based on based on adjuvant platform technology. The Company is engaged in the research and development (R&D) of premium preventive vaccines, therapeutic vaccines and immunotherapies such as hepatitis B virus (HBV) vaccines, chronic HBV vaccines and others. The Company is also engaged in the vaccines distribution and licensing out services.
Calendar
2024-08-08
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -17.79% | 89.79M | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- A261780 Stock
